Related Experiment Video
Updated: Aug 15, 2026
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model
1Department of Vascular and Endocrine Surgery, First Affiliated Hospital of the Fourth Military Medical University, Xi'an, Shaanxi Province, China. chenjh@fmmu.edu.cn
Abstract:
The antitumor effects of small-sized liposomal Adriamycin (LADR) administered by various routes were investigated in rabbits bearing well-developed VX2 tumors in the mammary gland. Rabbits received s.c. or i.v., or s.c. combined with i.v., injections of LADR 6 weeks after tumor implantation. The i.v. route showed a significant inhibitory effect on breast tumors and distant metastases. In comparison, metastases in axillary and mediastinal lymph nodes were more efficiently inhibited after s.c. injection. LADR administered concurrently by both the i.v. and s.c. routes produced satisfactory therapeutic activities on both primary breast tumors and metastases in local-regional lymph nodes, lungs and liver, as shown by slowed growth rates, decreased mRNA expression of proliferating cell nuclear antigen, and extensive necrosis and apoptosis of tumor cells. It is concluded that small-sized LADR administered s.c. provides reliable efficacy on lymphatic metastases of breast cancer and that the addition of treatment by the s.c. route to that by the conventional i.v. route can be recommended as a promising procedure to enhance chemotherapeutic effects in patients with metastatic breast cancer.
Insights
Small-sized liposomal Adriamycin (LADR) shows effectiveness against breast cancer. Combining subcutaneous (s.c.) and intravenous (i.v.) LADR administration enhances antitumor effects on primary tumors and metastases.
Area of Science:
- Oncology
- Pharmacology
- Nanotechnology
Background:
- Metastatic breast cancer remains a significant challenge, necessitating novel therapeutic strategies.
- Liposomal drug delivery systems offer potential for improved efficacy and reduced toxicity.
- Adriamycin (doxorubicin) is a cornerstone chemotherapy agent for breast cancer.
Purpose of the Study:
- To investigate the antitumor effects of small-sized liposomal Adriamycin (LADR) in a rabbit model of breast cancer.
- To compare the efficacy of LADR administered via subcutaneous (s.c.) and intravenous (i.v.) routes, individually and in combination.
- To evaluate LADR's impact on primary tumors, lymph node metastases, and distant organ metastases.
Main Methods:
- VX2 tumors were implanted in the mammary glands of rabbits.
- Rabbits received LADR via s.c. injection, i.v. injection, or a combination of both routes.
- Tumor growth, metastasis inhibition, and molecular markers (PCNA mRNA) were assessed.
- Histopathological analysis evaluated tumor necrosis and apoptosis.
Main Results:
- Intravenous LADR significantly inhibited primary breast tumors and distant metastases.
- Subcutaneous LADR demonstrated superior inhibition of axillary and mediastinal lymph node metastases.
- Combined s.c. and i.v. administration of LADR showed enhanced therapeutic activity against primary tumors and metastases in lymph nodes, lungs, and liver.
- Combined treatment led to slowed tumor growth, reduced PCNA mRNA expression, and increased tumor cell necrosis and apoptosis.
Conclusions:
- Small-sized LADR administered subcutaneously is effective against lymphatic breast cancer metastases.
- Combining s.c. and i.v. LADR administration is a promising approach to enhance chemotherapeutic outcomes in metastatic breast cancer patients.
- This combined route strategy warrants further investigation for clinical application in managing advanced breast cancer.
